Abstract: An improved process for preparing 1,1'-?1,4-phenylenebis-(methylene)!-bis-1,4,8,11-tetraazacyclotetradecane comprising the selective functionalization of an acyclic tetraamine, and subsequent dimerization and hydrolyzation/tosylation to obtain a 1,4-phenylenebis-methylene bridged hexatosyl acyclic precursor in a first step, the cyclization of said precursor to obtain a hexatosyl cyclam dimer in a second step, and the detosylation of said cyclam dimer in a third step followed by basification to obtain the desired 1,1'-?1,4-phenylenebis-(methylene)!-bis-1,4,8,11-tetraazacyclotetradecane.
Type:
Grant
Filed:
November 12, 1997
Date of Patent:
September 1, 1998
Assignee:
Johnson Matthey PLC
Inventors:
David Xu, Prasad Kapa, Oljan Repic, Thomas J. Blacklock
Abstract: An improved process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane comprising the selective functionalization of an acyclic tetraamine, and subsequent dimerization and hydrolyzation/tosylation to obtain a 1,4-phenylenebis-methylene bridged hexatosyl acyclic precursor in a first step, the cyclization of said precursor to obtain a hexatosyl cyclam dimer in a second step, and the detosylation of said cyclam dimer in a third step followed by basification to obtain the desired 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane.
Type:
Grant
Filed:
March 30, 1995
Date of Patent:
March 18, 1997
Assignee:
Johnson Matthey PLC
Inventors:
David Xu, Prasad Kapa, Oljan Repic, Thomas J. Blacklock
Abstract: An improved process for preparing 1,4,8,11-tetraazacyclotetradecane comprising the tetratosylation of an acyclic tetraamine to obtain a tetratoluenesulfonamide compound in a first step, the cyclization of said sulfonamide compound to obtain tetratosyl cyclam in a second step, and the detosylation of tetratosyl cyclam in a third step followed by basification to obtain the desired 1,4,8,11-tetraazacyclotetradecane.
Type:
Grant
Filed:
August 2, 1995
Date of Patent:
March 4, 1997
Assignee:
Johnson Matthey PLC
Inventors:
Lech Ciszewski, John Amedio, Prasad Kapa, Andrew Kucerovy, George T. Lee
Abstract: An improved process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane comprising the selective functionalization of an acyclic tetraamine to obtain an acyclic ditosyl intermediate and an acyclic tritosyl intermediate in a first step, the independent dimerization/tosylation of the ditosyl intermediate and dimerization of the tritosyl intermediate to obtain a 1,4-phenylenebis-methylene bridged hexatosyl acyclic precursor in a second step, the cyclization of said precursor to obtain a hexatosyl cyclam dimer in a third step, and the detosylation of said cyclam dimer in a fourth step followed by basification to obtain the desired 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane.
Abstract: Pharmaceutical compositions containing as active ingredients a linked cyclic compound of the general formula IZ--(A).sub.n --Y (I)in which Z and Y are independently cyclic polyamine moieties having from 9 to 32 ring members and from 3 to 8 amine nitrogen atoms in the ring, A is a linking atom or groups and n is O or an integer from 1 to 6, are indicated for the treatment of viral infections, and preventative administration, especially for retroviral infections.
Abstract: Platinum co-ordination compounds comprising at least one amine ligand and a functional group remotely bonded to the amine ligand, which functional group may be linkable to a monoclonal antibody to provide a moiety which stabilizes the antibody against in vivo hydrolysis.
Type:
Grant
Filed:
April 21, 1988
Date of Patent:
September 11, 1990
Assignee:
Johnson Matthey PLC
Inventors:
James G. Heffernan, Paul C. Hydes, Donald H. Picker
Abstract: A platinum co-ordination compound linkable to a monoclonal antibody by a functional group which forms part of a moiety which stabilizes the antibody against in vivo hydrolysis. Also the use of such compounds in the treatment of cancer.
Type:
Grant
Filed:
July 20, 1988
Date of Patent:
August 28, 1990
Assignee:
Johnson Matthey PLC
Inventors:
James G. Heffernan, Michael J. Cleare, Donald H. Picker
Abstract: A coordination compound of platinum suitable for the treatment of cancer and especially for oral administration has the general formula ##STR1## in which A is NH.sub.3 or cycloalkylamine, B is cycloalkylamine, and the R moieties are the same or different selected from H, lower alkyl etc. or form a cycloalkyl or cycloalkenyl group with the C atom.
Abstract: A bursting disc orientation device comprises a cut-away portion (7) on a predetermined one collar (2) of the bursting disc unit and cooperable with the cut-away portion, a projection (8) e.g. in the form of an arm of an angle bracket (9) secured to the periphery, or integral therewith, of that pipe flange (5) against which the said one collar (2) is required to bear. Thus, the unit can be prevented from being located between the pipe flanges of the bursting disc unit in other than a predetermined orientation in which the projection (8) is located in the cut-away portion (7). This improves the safety of the device.
Abstract: This invention relates to electrical connection means. In particular, the invention is concerned with means for effecting electrical connection between two or more bodies in such a way that any small relative movement between the bodies when so connected will result in only small to negligible mechanical stresses being imposed on one or more of the bodies and/or on one or more component parts of the electrical connection means. Further, electrical connection means according to the invention are such that, in service, they do not suffer from at least one of the disadvantages associated with known, substantially stress-free, electrical connection means. In more detail an electrical connection means comprises an electrically conductive member or lug dipping into and making electrical contact with liquid conductive material contained in an electrically conductive reservoir, and means for at least reducing any tendency towards expulsion of the liquid conductive material from the electrically conductive reservoir.
Abstract: A thermoplastic brazing alloy composition contains a particulate brazing alloy and a flux dispersed in a petroleum wax to form a solid suspension at room temperatures. Preferred petroleum waxes are paraffin wax and microcrystalline wax. On application to a workpiece and heating to brazing temperatures, the wax melts and leaves the brazing site and then volatilizes without leaving any carbonaceous residue and without causing any bubbling or blistering. The use of petroleum waxes is particularly useful when the flux contains a reactive material such as fluoroborate, a silicofluoride or an aluminofluoride.